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Background: Vitamin D3 and its analogues have recently been shown to enhance the anti-tumour effects
of 5- Fluorouracil (5-FU) both in vitro and in xenograft mouse model of colon cancer. This study measured
the potential mechanism(s) by which vitamin D3 could synergise the tumouricidal activities of 5-FU in
azoxymethane (AOM) rat model of colon cancer.
Methods: Seventy-five male Wistar rats were divided equally into 5 groups: Control, AOM, AOM-treated by
5-FU (5-FU), AOM-treated by vitamin D3 (VitD3), and AOM-treated by 5-FU + vitamin D3 (5-FU/D). The study
duration was 15 weeks. AOM was injected subcutaneously for 2 weeks (15 mg/kg/week). 5-FU was injected
intraperitoneally in the 9th and 10th weeks post AOM (8 total injections were given: 12 mg/kg/day for
4 successive days, then 6 mg/kg every other day for another 4 doses) and oral vitamin D3 (500 IU/rat/day;
3 days/week) was given from week 7 post AOM till the last week of the study. The colons were collected
following euthanasia for gross and histopathological examination. The expression of β-catenin, transforming
growth factor-β1 (TGF-β1), TGF-β type 2 receptor (TGF-βR2), smad4, inducible nitric oxide synthase (iNOS),
and heat shock protein-90 (HSP-90) proteins was measured by immunohistochemistry. In colonic tissue
homogenates, quantitative RT-PCR was used to measure the mRNA expression of Wnt, β-catenin, Dickkopf-1
(DKK-1) and cyclooxygenase-2 (COX-2) genes, while ELISA was used to measure the concentrations of
TGF-β1, HSP-90 and COX-2 proteins.
Results: Monotherapy with 5-FU or vitamin D3 significantly decreased the number of grown tumours induced by
AOM (P < 0.05); however, their combination resulted in more significant tumouricidal effects (P < 0.05) compared with
monotherapy groups. Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt,
β-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-β1, TGF-βR2, smad4
(P < 0.05), in comparison with their corresponding monotherapy groups.
Conclusions: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/β-catenin
pathway, TGF-β1 signals, iNOS, COX-2 and HSP-90. Further studies are required to illustrate the clinical value of vitamin D
supplementation during the treatment of colon cancer with 5-FU in human patients.
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Colorectal cancer (CRC) is the third most common ma-
lignancy and is ranked as the fourth leading cause of
deaths from cancer worldwide according to the World
Health Organization [1]. Azoxymethane (AOM) is com-
monly used in rodents to create an experimental model
of colon cancer that mimics the sporadic phenotype in
human with high similarities in molecular, clinical and
histopathological features of the disease between both
species [2–4]. AOM has therefore been extensively used
in the study of the molecular biology, prevention and
treatment of CRC [2, 4]. Metabolites of AOM cause mu-
tagenesis of colon glandular epithelial cells DNA by re-
placing the nucleotides from G:C to A:T and the
required duration for the development of AOM-induced
colon cancer is 14 weeks in rodents [2, 4, 5].
Pathological alterations in several molecular pathways
have been identified in the tumorigenesis of colon can-
cer. These molecules include transforming growth factor
(TGF)-β and its related molecules, Wnt/β-catenin path-
way, inducible nitric oxide synthase (iNOS), heat shock
protein (HSP)-90 and cyclooxygenase (COX)-2 [2].
TGF-β inhibits the growth of normal epithelial cells and
it has been found that cancer cells become resistant to
the growth inhibitory effect of the molecule. Possible
mechanisms of resistance include a decrease in the ex-
pression of the protein, its type 2 receptor and mutation
of its intracellular mediators, smad2 and 4, in both hu-
man and rodent model of colon cancer [6–8]. Another
major pathogenic mechanism of CRC is based on the
abnormal increase in the expression of Wnt molecule
that results in the stabilization of β-catenin and its
localization in the nucleus. This effect is inhibited by
Dickkopf (DKK) family and DKK-1 is the most exten-
sively studied member of the family [9–11].
Other studies have also demonstrated that iNOS and
COX-2 play a crucial role in the development of colon
cancer in human and AOM-induced model in rodents
as both are pro-angiogenic molecules and they promote
tumour angiogenesis, which is a vital step for the pro-
gression and spread of solid tumours [12–14]. Further-
more, The use of iNOS inhibitors and non-steroidal
anti-inflammatory drugs, such as COX-2 inhibitors, have
shown to exhibit antitumor properties by several studies
[14, 15]. HSP-90 is another molecule involved in the
pathogenic mechanisms of colon cancer. HSP-90 regu-
lates protein folding and trafficking in normal cells and
blocking the activities of HSP-90 has been shown to
delay the progression of colon cancer in vitro and
in vivo by several mechanisms [16–18].
Surgical removal of colon cancer is the most effective
therapeutic approach but it requires early diagnosis [19]. In
advanced stages of the disease, chemotherapy and radio-
therapy are other alternative approaches [20, 21]. One ofthe most common chemotherapeutic agents used for the
treatment of CRC is 5-Fluorouracil (5-FU) [20–22]. How-
ever, the success of achieving significant suppression of can-
cer by chemotherapy is rare and the 5 years survival rate
for metastatic colon cancer is < 10 % [20, 21, 23, 24]. Hence,
understating the cancer biology and its related patho-
physiological mechanisms is necessary for the development
of effective therapeutic strategies. A possible approach to
achieve such development is the combination of other
agents that could enhance the therapeutic effect of 5-FU.
Many studies have proposed vitamin D and calcium
as effective chemopreventive agents against the devel-
opment of CRC in human and chemically induced
rodent models [25–28]. Vitamin D is also involved
in the regulation of cell proliferation, differentiation,
apoptosis, cell cycle and angiogenesis [22, 29]. Several
other reports have also shown positive effects of com-
bining active vitamin D or its analogues with a variety
of chemotherapeutic agents in the treatment of differ-
ent cancers [30–32]. Recently, supplementation with
vitamin D analogues has been shown to increase the
sensitivity of colon cancer cells to 5-FU and to en-
hance the cytotoxic effects of the drug both in vitro
and in vivo [22, 33–35].
These aforementioned findings suggest that combining
vitamin D and 5-FU may be promising in the treatment
of CRC. The current study therefore measured the ef-
fects of combining vitamin D3 with 5-FU on colon can-
cer regression and the expression of Wnt/β-catenin,
TGF-β1 and its related molecules, HSP-90, iNOS and
COX-2 in an intermediate (15 weeks) AOM experimen-
tal model in rat. A better understanding of the mecha-
nisms by which vitamin D enhances the cytotoxic
efficacy of 5-FU may provide a better therapeutic ap-
proach for the treatment of colon cancer, especially in
those patients with advanced stages of the disease.
Methods
Drugs
AOM and 5-FU were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Vitamin D3 (cholecalciferol 4500 IU/
mL) oral drops (VitD3, Novartis International AG, Basel,
Switzerland) was used in the study.
Study design
All experimental protocols were approved by the Com-
mittee for the Care and Use of Laboratory Animals at
Umm Al-Qura University and were in accordance with
the EU Directive 2010/63/EU for animal experiments.
A total of 75 male Wistar rats weighing 200–250 gm
were used. All animals received humane care during the
study protocol and during euthanasia. The animals were
housed in clean and sterile polyvinyl cages (5 rats/cage),
maintained on standard laboratory pellet diet and water
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conditioned at 22–24 °C and 12 h dark/light cycle. After
acclimation, the rats were randomly categorised into 5
groups (15 rats/group) as follows: The first group served
as ‘Control group’, the second group consisted of those
that only received AOM ‘AOM group’, the third group
received AOM+ 5-FU ‘5-FU group’, The fourth group
received AOM+ vitamin D ‘VitD group’ and the last
group consisted of those that received AOM+ 5-FU +
VitD ‘5-FU/D group’.
Treatment protocol
AOM was dissolved in normal saline and injected
subcutaneously to the animals at a dose of 15 mg/kg
body weight, once weekly for a total of 2 weeks to in-
duce tumorigenesis in the colon as previously de-
scribed [24]. 5-FU was dissolved in normal saline and
injected intraperitoneally to the designated groups
during the 9th and 10th weeks of the study in a dos-
age regimen similar to that used for the treatment of
colon cancer in human (8 total injections were given:
12 mg/kg/day for 4 successive days, then 6 mg/kg
every other day for another 4 doses). The drugs were
prepared fresh on the day of use.
Cholecalciferol (4500 IU/mL) was prepared by adding
4 ml to 16 ml saline every morning to form a final con-
centration of 1000 IU/mL. Each rat in the ‘VitD’ and ‘5-
FU/D’ groups received 0.5 ml/day (500 IU/day; 3 days/
week) by oral gavage from week 7 post AOM till the last
week of the study protocol. Cholecalciferol and its dose
were chosen over calcitriol, the hormonal form of vita-
min D, to avoid the risk of soft tissue calcification [36].
Types of samples
Rats were fasted overnight and subsequently euthanised
under anaesthesia using diethyl ether (Fisher Scientific
UK Ltd, Loughborough, UK). Three ml of blood were
collected from each rat in a plain tube immediately after
cutting the vena cava. The samples were centrifuged and
the serum was stored in −20 °C till used to measure the
serum levels of liver enzymes (ALP, ALT and AST), renal
function parameters (creatinine, BUN and urea) and
serum concentrations of 25-OH vitamin D using Cobas
e411 (Roche Diagnostics International Ltd, Switzerland)
according to the manufacturer’s protocol.
Whole colon from rectum to caecum was gently
resected, flushed with cold potassium phosphate buffer
(0.1 M, pH 7.2) to remove residual bowel contents, slit
opened longitudinally, its length was measured, and then
submerged overnight in 10 % (v/v) neutralised formalin
with the mucosa on the upper side between layers of fil-
ter papers. The length and width of the isolated colons
were measured to calculate the colon surface area as fol-
low: Length X Width in cm2. All colon specimens werethen processed for gross and histopathological examin-
ation and later for immunohistochemistry, ELISA and
quantitative gene expression.
Gross and microscopic quantification of tumours
The grown tumours on colon mucosa were counted by
2 blinded observers to the source group by naked eye.
Next, the formalin-fixed tissues were cut into proximal,
middle and distal segments of the same length. Each
segment was stained with 0.2 % methylene blue solution
for 1.5–2 min, placed on a microscope slide with the
mucosal side upward, and then observed under a dis-
secting microscope to examine and count the numbers
of small tumours that were not detected by naked eye.
All segments of each colon were also examined by two
observers who were blind to the source group.
A micro-feather scalpel blade was used under the dis-
secting microscopy to excise the tumours of interest
from the surrounding normal tissues to be used for
histopathological, immunohistochemical and molecular
examinations. Two specimens were processed for histo-
pathology, 2 specimens for immunohistochemistry and
the remaining were distributed equally either in RIPA
buffer (Santa-Cruz Biotechnology Inc, Burlingame, CA)
for protein extraction or RNALater (Ambion, Thermo
Fisher Scientific, USA) for preservation in −80 °C till
processed for quantitative RT-PCR.
Histopathological examination
Following de-staining from methylene blue with 80 %
ethanol, the tissue specimens were processed by a con-
ventional method, embedded in paraffin and sectioned
at 4–5 μm, and stained by haematoxylin and eosin
(H&E) for histopathology. Aberrant crypt foci (ACF) and
glandular epithelial morphology were examined by an
expert histopathologist who was blind to the specimen
group. Based on the crypt architecture and nuclear features,
ACF were microscopically classified into hyperplastic ACF
(no dysplasia) or dysplastic ACF (elongated, crowded and
pseudo-stratified nuclei; increased nucleus-to-cytoplasm ra-
tio; reduced number of goblet cells; back-to-back glands
and markedly decreased interglandular stroma) similarly to
the previously established and published criteria [37]. A
colonic adenoma consisted of proliferative/hyperplastic co-
lonic glands, while a colonic adenocarcinoma was charac-
terised by dysplastic glands that invaded the submucosal
muscle layer [4].
Immunohistochemistry
Polyclonal goat IgG antibodies to detect TGF-β1 (C-16),
smad4 (C-20), β-catenin (C-18), and polyclonal rabbit
IgG antibodies against TGF-β type II receptor (L-21),
iNOS (N-20) and HSP-90-α/β (N-17) were obtained
from Santa-Cruz Biotechnology Inc (Burlingame, CA).
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used to localise the proteins of interest. Briefly, paraffin
embedded sections of 5 μm thickness were dewaxed in
xylene, dehydrated in alcohol, and treated with 2 % (vol/
vol) hydrogen peroxide for 20 minutes in methanol to
block endogenous peroxidase. All sections were pre-
treated in an 850-watt domestic microwave oven in
0.01 M citrate buffer for 3 minutes. The sections were
incubated for 30 minutes with normal donkey or normal
goat serum for primary goat and rabbit IgG antibodies,
respectively. The sections were then incubated with the
primary antibodies (the antibody concentration was
1:100 for all used antibodies) over night at 4 °C.
The following day the sections were washed with
20 mM PBS (pH 7.3) and then incubated with 1:200 bio-
tinylated anti-goat or anti-rabbit secondary antibodies
for 30 minutes. After a further wash step, the sections
were incubated with the avidin-biotin peroxidase
complex ABC system (Santa-Cruz Biotechnology Inc,
Burlingame, CA) for 30 minutes and then subsequently
with 3, 3′-diaminobenzidine (Santa-Cruz Biotechnology
Inc, Burlingame, CA) for 10 minutes. Sections were
washed in tap water, counter stained with Gill’s haema-
toxylin, then dehydrated in a series of graded ethanol,
cleared in xylene, and mounted in DPX (BDH/Merck,
Leicestershire, UK). The negative control slides consisted
of a section of the tissue block being studied, which was
treated identically to all other slides, with the exception
that the primary antibody was omitted to control for
non-specific binding of the detection system.
For evaluation and scoring of immunohistochemical
staining, the sections were observed on a Labor Lux mi-
croscope (Leitz, Wetzlar, Germany), at a magnification of
×100, ×200 and ×400. A positive reaction was characterised
by the presence of brown staining. Each section was exam-
ined by two observers who were blinded to the source of
tissue and the intensity of staining was assessed using the
‘H score’ which was calculated using the following formula
[38]: H score =∑Pί (ί +1), where ί represents the intensity
of staining (0 = negative; 1 = weak; 2 =moderate and 3 =
strong) and Pί is the percentage of cells (0–100 %) stained
at each intensity.
In the case of a wide disagreement between the two
observers, the slides were reanalysed by a third inde-
pendent reviewer. The final result was obtained by aver-
aging the individual observer results. Representative
sections were photographed using an Olympus digital
camera at ×200 magnification.
Enzyme linked immunosorbant assay (ELISA)
Two specimens measuring 1 cm each that involved
tumours (except for the control group) were obtained
from each colon following excision under dissecting
microscope and they were used immediately for proteinextraction using 2 ml of RIPA lysis buffer containing
protease inhibitors (Santa-Cruz Biotechnology Inc,
Burlingame, CA) and electrical homogeniser. All homo-
genated samples were centrifuged at 14000 rpm for
30 minutes and small aliquots (0.5 ml) of the resultant
supernatant were placed in Eppendorf tubes and stored
in −20 °C till processed to measure the levels of candi-
date proteins in colon using ELISA.
The concentrations of total proteins extracted from
the colon tissue homogenates were measured using
the BioSpec-nano (Shimadzu Corporation, Japan) at
280 OD. All protein samples were diluted using nor-
mal sterile saline to make a final concentration of
500 μg/ml of total protein.
The concentrations of TGF-β1, HSP-90α proteins
and COX-2 enzyme in the tissue homogenates were
measured using ELISA. All samples were processed in
duplicate on a fully automated ELISA system (Human
Diagnostics, Germany) and according the manufac-
turers’ instructions. The used ELISA kits were pur-
chased from Cusabio (Hubei, China) for HSP-90 and
COX-2, and R&D systems (Minneapolis, USA) for
TGF-β1.
As reported by the manufacturers, the HSP-90α had a
detection range between 0.312 to 20 ng/mL with a sensi-
tivity < 0.078 ng/mL, intra-assay precision <8 % and inter-
assay precision <10 %. The detection range of the COX-2
kit was 1.56-100 ng/mL, with a sensitivity <0.39 ng/mL,
intra-assay precision <8 % and inter-assay precision
<10 %. The TGF-β1 kit had a detection range between
31.2-2,000 pg/mL, sensitivity of 4.6 pg/mL, intra-assay
and inter-assay precisions of <4 % and <10 %, respectively.
RNA extraction and cDNA synthesis
Total RNA was isolated from the stored colonic speci-
mens in RNALater following homogenisation of the
specimens and by using the Purelink RNA mini kit from
Life Technologies (Thermo Fisher Scientific, CA, USA)
and according to the manufacturer’s instructions. RNA
was treated with RNAse-free DNAse during the extrac-
tion protocol to avoid the collection of genomic DNA
and the concentrations and quality of the extracted total
RNA were measured using the BioSpec-nano (Shimadzu
Corporation, Japan), and its quality and integrity were
concluded through the A260/A280 ratio.
For cDNA synthesis, 200 ng of total RNA was tran-
scribed to cDNA using a high capacity RNA-to-cDNA
Reverse Transcription Kit from Applied Biosystems,
(Thermo Fisher Scientific, Warrington, UK) following the
manufacturer’s protocol.
Quantitative RT-PCR
Quantitative RT-PCR was performed using the 2-ΔΔCt
method on the following 4 target rat genes: Wnt
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(NM_001106350.1) and COX-2 (AF233596.1). The re-
sults were normalised against the Ct values of β-actin
(NM_031144.3) and expressed as fold-change compared
with the normal control group. The nucleotides primer
sequences are listed in Table 1.
PCR reactions were carried out by using power SYBR
green master mix from Applied Biosystems, (Thermo
Fisher Scientific, Warrington, UK) and a step one Real
Time PCR system (Applied Biosystems, USA) in tripli-
cate wells. Each well of the PCR plate contained 10 μl
SYBR Green, 7 μl DNase/RNase free water, 1 μl of each
primer (5 pmol) and 1 μl cDNA (25 ng). The amplifica-
tion was performed under the following conditions:
40 cycles (95 °C 15 s and 60 °C 1 min). Two negative
controls were included, one with minus-reverse tran-
scription (minus-RT) control from the previous reverse
transcription step and a minus-template PCR, which
contained all the PCR components but water was used
as a template.
Statistical analysis
Statistical analysis of the results was performed using
SPSS version 16. Normality and homogeneity of data
were assessed with the Kolmogorov-Smirnov test and
Levene test, respectively. One way ANOVA followed by
LSD post hoc test were used to compare between the
different groups. Data are expressed as mean ± standard
deviation and P value < 0.05 was considered significant.
Results
Routine biochemistry
There was no significant difference (P > 0.05) between
the different study groups in body weight, liver en-
zymes and renal function parameters (Table 2). How-
ever, serum concentrations of total 25-OH Vitamin D
were significantly higher in the VitD (P = 0.01 × 10−4)
and 5-FU/D (P = 0.0002) groups that received cho-
lecalciferol compared with the other study groups
(Table 2).
Quantification of tumours and histopathological findings
Administration of AOM had resulted in the forma-
tion of tumours on the mucosal surface of all colonTable 1 The sequences of PCR primers used for the detection of β-
corresponding genes accession numbers
Forwards
β-actin (NCBI: NM_031144.3) 5′ CGG TCA GGT CAT C
Wnt (NCBI: NM_001105714.1) 5′ AGC TGG GTT TCT GC
β-Catenin (NCBI: AF397179.1) 5′ TTC CTG AGC TGA CC
DKK-1 (NCBI: NM_001106350.1) 5′ ATT CCA GCG CTG TT
COX-2 (NCBI: AF233596.1) 5′ AAT CGC TGT ACA Aspecimens collected from the injected groups. However,
in rats injected with AOM and then treated with 5-FU,
vitamin D, or a combination of both drugs there was a
significant decrease in the numbers of grown tumours as
detected by gross and dissecting microscope examination
(Table 2). The lowest number of tumours was observed
in the ‘5-FU/D group’ compared with the other treatment
groups (Fig. 1; panel 5a). Furthermore, the number of
tumours/colon surface area ratio (NT/CS) was also sig-
nificantly lower in the ‘5-FU’ (P = 0.02), ‘VitD’ (P = 0.04 ×
10−2) and ‘5-FU/D’ (P = 0.02 × 10−5) groups compared
with the ‘AOM group’ (Table 2).
Examination by dissecting microscope following me-
thylene blue staining showed normal mucosal and crypt
appearance in the control group (Fig. 1; panel 1b). The
AOM group demonstrated several micro-tumours and
significant alteration of the mucosal surface (Fig. 1; panel
2b). Treatment with 5-FU significantly decreased the
numbers of tumours but the colonic mucosal architec-
ture was distorted (Fig. 1; panel 3b). Similar effect on
the numbers of observed tumours under the microscope
was also seen in the group treated with vitamin D3
monotherapy. However, the distortion of the mucosal
topographic features was less marked compared with the
‘AOM’ and ‘5-FU’ groups (Fig. 1; panel 4b). The com-
bination of vitamin D3 with 5-FU also preserved/re-
stored the mucosal architecture compared with ‘AOM’
and ‘5-FU’ groups (Fig. 1; panel 5b).
Histopathological examination showed the growing of
multiple tubular adenomas and the presence of many
large ACF (>4 crypt/focus) with hyperplastic and dys-
plastic glandular epithelium in the colon specimens col-
lected from the ‘AOM group’ (Fig. 1; panel 2c). Only 2
rats of the AOM group developed adenocarcinoma while
the remaining study groups were free.
The use of 5-FU alone following AOM injections
showed a significant reduction in the numbers of
large ACF and the thickness of the colon mucosa
compared with AOM group (P = 0.01 × 10−6). How-
ever, marked hyperplasia and high grade dysplasia of
the glandular epithelial cells were observed despite
the observed decrease in the quantities of large ACF
(Fig. 1; panel 3c). The use of cholecalciferol (vitamin
D3) either alone (P = 0.03 × 10−7) or in combinationactin, Wnt, β-catenin, DKK-1 and COX-2 including the
Reverse
AC TAT CG 3′ 5′ TTC CAT ACC CAG GAA GGA AG 3′
T ACG TT 3′ 5′ AAT CTG TCA GCA GGT TCG TG 3′
A AAC TG 3′ 5′ GCA CTA TGG CAG ACA CCA TC 3′
A CTG TG 3′ 5′ GAA TTG CTG GTT TGA TGG TG 3′
GC AGT GG 3′ 5′ GCA GCC ATT TCT TTC TCT CC 3′
Table 2 Mean ± SD of body weight, colon surface area (length × width in cm), count of colonic tumours by gross and dissecting
microscope, large ACF, number of tumour/colon surface area ratio (NT/CS), serum 25-OH vitamin D concentrations, liver enzymes
and renal function parameters and in the different study groups
Normal group AOM group 5-FU group VitD group 5-FU/D group
Body weight (g) 231.57 ± 20.01 221.97 ± 23.01 238.42 ± 13.64 230.1 ± 22.2 229.5 ± 18.7
Colon surface area (cm2) 19.1 ± 2.2 18.89 ± 3.43 19.81 ± 1.84 21.5 ± 2.29 20.4 ± 4.1
Tumour count Gross N/A 12.5 ± 3.21 8.7 ± 2.9** 8.1 ± 2.5** 6.2 ± 1.6**,***
Dissecting
Microscope
N/A 17.36 ± 4.6 8.8 ± 1.75** 10.04 ± 3.6** 5.78 ± 1.1**,***,****
Total N/A 29.16 ± 2.92 16.66 ± 4.41** 19.33 ± 1.8** 11.5 ± 1.65**,***,****
large ACF (with≥ 4 crypts/focus) 0 41.3 ± 8.0 21.3 ± 5.3** 19.7 ± 7.6** 11.2 ± 4.2**,***,****
NT/CS Ratio N/A 1.5 ± 0.14 0.83 ± 0.14** 0.86 ± 0.06** 0.6 ± 0.18**,***,****
25-OH Vitamin D (ng/mL) 46.19 ± 8.1 36.6 ± 6.7* 35.7 ± 9.5* 68.5 ± 9.1*,**,*** 65.8 ± 9.1*,**,***
ALP (IU/L) 122.6 ± 11.2 125.7 ± 9.7 120.8 ± 12.4 127.3 ± 11.9 121.6 ± 11.1
ALT (U/L) 67 ± 2.4 71.2 ± 6.7 68.7 ± 4.1 66.4 ± 5.3 67.3 ± 3.7
AST (U/L) 92.4 ± 24.2 105.8 ± 26.7 109 ± 21.6 103 ± 19.8 99 ± 11.9
Creatinine (mg/dL) 0.22 ± 0.03 0.2 ± 0.06 0.2 ± 0.03 0.19 ± 0.03 0.21 ± 0.05
Urea (mg/dL) 47.6 ± 5.1 52.3 ± 4 51.6 ± 9.5 47.3 ± 5.8 49.1 ± 3.7
BUN (mg/dL) 22.2 ± 2.4 24.4 ± 1.9 26.3 ± 4.4 22 ± 2.7 21.4 ± 2.1
*P < 0.05 compared with normal; **P < 0.05 compared with AOM group, ***P < 0.05 compared with 5-FU group and ****P < 0.05 compared with VitD group
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of large ACF compared with AOM group and the
lowest numbers were observed in the ‘5-FU/D’ group
(Table 2). Furthermore, glandular dysplasia was less
frequently observed and it was characterised of being
of low grade in the groups treated with vitamin D3
compared with the other groups (Fig. 1; panel 4c and
5c). Nevertheless, vitamin D3 did not prevent/restore
glandular epithelial hyperplasia in the treated groups.
Immunohistochemistry findings
Immunostaining of normal colon specimens obtained
from the control group showed that the expression of
TGF-β1, its type II receptor and smad4 was localised in
the cytoplasm of the glandular epithelium. In the AOM
group, a significant decrease in the expression of the
three proteins was observed, especially in glands with
marked dysplasia (Fig. 2b, g and l). A significant in-
crease in the expression of TGF-β1 and its related
molecules was noted following the treatment with
5-FU (P = 0.04 × 10−3), vitamin D3 (P = 0.05 × 10−5)
and 5-FU + vitamin D3 (P = 0.02 × 10−4) (Table 3).
The highest increase in the expression of the candi-
date molecules was observed with the ‘5-FU/D’ group
compared with the other study groups including con-
trol (Table 3).
On the other hand, the immunostaining of β-catenin,
iNOS and HSP-90 was weak in the glandular epithelium
of normal colon and the expression was scattered and
only detected in few glandular cells (Fig. 3a, f and k). A
significant increase in the intensity of the immunostainwas observed in the ‘AOM’ group for β-catenin (P = 0.01
× 10−8), iNOS (P = 0.01 × 10−5) and HSP-90 (P = 0.03 ×
10−6) compared with control. All proteins showed cyto-
plasmic expression except for β-catenin which exhibited
strong nuclear staining (Fig. 3b, g and l). A marked
decrease in the expression of β-catenin, iNOS and
HSP-90 was seen in the ‘5-FU’ (P = 0.03 × 10−4; P =
0.05 × 10−6 and P = 0.03 × 10−5, respectively), ‘VitD’
(P = 0.002; P = 0.04 × 10−3 and P = 0.02 × 10−6, respect-
ively) and ‘5-FU/D’ (P = 0.02 × 10−5; P = 0.07 × 10−5 and
P = 0.01 × 10−8, respectively) groups when compared
with ‘AOM group’ (Table 3). No staining was observed in
all negative controls (data not shown).
ELISA
The concentrations of TGF-β1 protein in the colon tis-
sue homogenates showed a significant decrease in the
‘AOM group’ (294.7 ± 61.4 pg/mL; P = 0.003) compared
with ‘control group’ (529.6 ± 97.8 pg/mL). A significant
increase in the protein concentrations was observed in
the ‘5-FU’ (475.2 ± 96 pg/mL; P = 0.006 × 10−3), ‘VitD’
(505.6 ± 56.3 pg/mL; P = 0.03 × 10−4) and ‘5-FU/D’
(600.2 ± 48.7 pg/mL; P = 0.02 × 10−5) groups (Fig. 4).
A significant increase in the concentrations of HSP-90α
was detected in the tissue homogenates collected from the
‘AOM group’ (0.53 ± 0.15 ng/mL; P = 0.007 × 10−7) when
compared with those obtained from the ‘control group’
(0.18 ± 0.1 ng/mL). Treatment with 5-FU (0.23 ± 0.1 ng/
mL; P = 0.0003), vitamin D (0.24 ± 0.06 ng/mL; P = 0.002)
and 5-FU/D (0.22 ± 0.05 ng/mL; P = 0.02 × 10−4) was
associated with a significant decrease in the protein
Fig 1 Gross and microscopic appearance of colon mucosa in (1) control group, (2) AOM group, (3) 5-FU group, (4) vitamin D group and (5) 5-FU/D
group. Colonic mucosa was examined by (Panel a): Gross; (Panel b): dissecting microscopy following staining with 0.2 % methylene blue and
(Panel c): light microscopy at magnifications ×100 and ×200 following staining with H&E. (Black arrow head = tumour observed by naked eye;
red star = large ACF [>4 crypts/focus]; light blue arrow = hyperplasia and green arrow = dysplasia)
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ever, there was no significant difference between the three
treatment groups (Fig. 4).
The concentrations of COX-2 increased significantly
in the ‘AOM’ group (25.8 ± 5.5 ng/mL; P = 0.01 × 10−5)compared with the control group (3.83 ± 1.28 ng/mL).
Treatment with 5-FU (10.1 ± 3.4 ng/mL; P = 0.0004),
vitamin D (11.2 ± 3.4 ng/mL; P = 0.02 × 10−3) or combi-
ning both drugs (9.1 ± 2.7 ng/mL; P = 0.005 × 10−3) signifi-
cantly reduced the levels of COX-2 in tissue homogenates
Fig 2 Immunohistochemistry localisation of TGF-β1 (left column), TGF-β type 2 receptor (middle column) and smad4 (right column) in control
(a, f & k), AOM (b, g & l), 5-FU (c, h & m), VitD (d, i & n) and 5-FU/D (e, j & o) groups. (×200 magnification, scale bar = 8 μm)
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significantly higher than the control group (Fig. 4).
Quantitative RT-PCR
Gene expression study showed a significant increase
in the mRNA expression of Wnt (5 folds; P = 0.001),
β-catenin (3.8 folds; P = 0.03) and COX-2 (5 folds;
P = 0.0002), and a significant decrease in the gene expres-
sion of DKK-1 (4 folds; P = 0.0002) in the ‘AOM group’
when compared with the ‘control group’. Treatment eitherwith 5-FU, vitamin D3 or dual therapy significantly altered
the gene expression of the aforementioned genes com-
pared with the ‘AOM group’ (Fig. 5).
Discussion
Herein, we examined the effects of vitamin D3 therapy
alone and in combination with 5-FU for the treatment
of colon cancer induced in rats by AOM. The current
study also measured the possible synergistic interactions
between vitamin D3 and 5-FU in the regulation of cell
Table 3 Mean ± SD of immunohistochemistry scores for TGF-β1, TGF-β receptor II, Smad 4, β-catenin, iNOS and HSP-90 proteins in
colon specimens
Normal group AOM group 5-FU group VitD group 5-FU/D group
TGF-β1 315.5 ± 31.2 136.4 ± 23.4* 301.48 ± 44.3** 323.9 ± 38.5** 348.1 ± 27.8*,**,***
TGF-β receptor II 333.7 ± 28.7 121.4 ± 19.2* 135.7 ± 17.6* 229.2 ± 26.8*,**,*** 377.2 ± 17.8*,**,***,****
Smad 4 301.1 ± 26 147.2 ± 20.3* 216.1 ± 23.9*,** 258.7 ± 31.6*,**,*** 386.3 ± 12.2*,**,***,****
β-catenin 61 ± 16.7 370.6 ± 28.7* 267.6 ± 35.3*,** 259.6 ± 30.1*,** 149.7 ± 22.6*,**,***,****
iNOS 39.4 ± 9.5 373.1 ± 26.8* 261.8 ± 47.2*,** 188.1 ± 33.6*,**,*** 113.1 ± 21.6*,**,***,****
HSP-90 112.7 ± 27.6 376.5 ± 22.6* 302.4 ± 36.8*,** 174.7 ± 28.6*,**,*** 88 ± 15.4*,**,***,****
*P < 0.05 compared with normal; **P < 0.05 compared with AOM group, ***P < 0.05 compared with 5-FU group and ****P < 0.05 compared with VitD group
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cancer at the molecular level by measuring the expres-
sion patterns of Wnt/β-catenin pathway, TGF-β and its
related molecules, HSP-90, COX-2 and iNOS at the pro-
tein and gene levels.
Gross and microscopic findings of this study showed
that monotherapy with 5-FU, in a similar dosage regi-
men to that applied for the treatment of CRC in human,
significantly reduced the progression of the induced
colon cancer in AOM-injected rats. Nevertheless, dis-
ruption of the mucosal topography, marked hyperplasia
and high grade dysplasia of the glandular epithelium
were frequent despite the reduction in the numbers of
tumours. At the molecular level, 5-FU increased the ex-
pression of TGF-β1 protein, its type 2 receptor and
intracellular mediator smad4. Moreover, 5-FU signifi-
cantly reduced the expression of β-catenin protein and
Wnt mRNA, and significantly increased the DKK-1
mRNA expression. The expression of HSP-90, iNOS and
COX-2 were also significantly decreased following treat-
ment with 5-FU monotherapy.
Our results further demonstrated that therapy with
vitamin D3 had similar effects to 5-FU monotherapy re-
garding the tumour regression and the expression of
candidate molecules. Interestingly, a significant additive
anti-tumour effect was obtained from co-therapy with 5-
FU and vitamin D3, whereby the most recorded reduc-
tion in the numbers of tumours, decrease in the grade of
cellular dysplasia and modulation of the candidate pro-
and anti-tumorigenesis molecules were observed in the
rats treated with 5-FU/vitamin D3 dual therapy. Further-
more, vitamin D3 ± 5-FU preserved the topographic
architecture of the colon mucosa and decreased the level
of cellular dysplasia but not hyperplasia. Our findings
suggest that vitamin D enhances the tumouricidal effects
of 5-FU against colon cancer probably by modulating
several molecular pathways involved in cell growth, dif-
ferentiation, DNA damage and angiogenesis.
The importance of vitamin D in the prevention
and/or treatment of a variety of cancers, including
colon cancer, have been suggested by several studies
[39]. The anti-cancer properties of vitamin D caninfluence the process of proliferation, differentiation
and apoptosis of human colon cancer cells mainly
through vitamin D receptor (VDR) [40]. This is fur-
ther supported by the observation that VDR−/− null
mice had increased susceptibility to carcinogenesis
due to increasing oxidative DNA damage and al-
teration in the balance between proliferation and
apoptosis [41]. The growth of cancer has also been
reported to be more aggressive with vitamin D defi-
ciency in a mouse MC-26 model of colon cancer [26]
and dietary vitamin D significantly reduced the in-
cidence of colonic tumours in rodents treated with
carcinogens [42, 43]. A significant reduction in the
number of carcinogens induced tumours has also
been shown following the administration of vitamin
D3 or several of its analogues [44].
Our results correlate with the aforementioned reports
as they showed a significant decrease in the number of
colon tumours following treatment with vitamin D. Add-
itionally, vitamin D was associated with less frequent cel-
lular dysplasia of the glandular epithelium. The present
findings support the notion that supplementation with
vitamin D may decrease and/or reduce the aggressive-
ness of colon cancer growth and progression.
Despite being a standard anti-CRC chemotherapeutic
agent, 5-FU exhibits only limited efficacy when used as a
single agent with objective tumour responses from 7-
17 % and with a median survival time <1 year [45]. Fur-
thermore, the combination of 5-FU with irinotecan and
Leucovorin for the treatment of metastatic CRC cases is
also associated with low response rate ranging between
35- 39 % [45]. Thus, there is a compelling need to de-
velop new therapeutic strategies for the treatment of
CRC. One possible approach could be by combining nat-
ural biological agents that possess anticancer properties
to improve the therapeutic efficacy of the currently used
anticancer therapy [46].
The combination of vitamin D3 with 5-FU in the
present study increased the tumouricidal effects of the
cytotoxic drug and it was associated with the lowest
numbers of tumours compared either with 5-FU or
vitamin D monotherapy. These observations suggest a
Fig 3 Immunohistochemistry localisation of β-catenin (left column), iNOS (middle column) and HSP-90 (right column) in control (a, f & k),
AOM (b, g & l), 5-FU (c, h & m), VitD (d, i & n) and 5-FU/D (e, j & o) groups. (×200 magnification, scale bar = 8 μm)
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colon cancer and this is in agreement with several re-
cently published reports. A research group has lately
shown that the cellular sensitivity to chemotherapy
increased significantly following supplementation with
either vitamin D or its analogues through promoting the
synthesis of calcium sensing receptor (CaSR) in vitro
[33, 34]. Similar results have also been reported by
Milczarek et al. who have demonstrated that the vitamin
D analogues, PRI-2191 and PRI-2205, resulted in asignificant increase in the expression of VDR and signifi-
cantly promoted the chemosensitivity of cancer cells to
5-FU therapy in MC38 mouse colon cancer and, HT-29
cell line in vitro and in a xenograft mouse model of
colon cancer [22, 35]. Both analogues enhanced the anti-
metastatic activity and prolonged the anti-tumour effect
of chemotherapy in a dose dependent manner.
These findings, in addition to our observations, indi-
cate a potential beneficial effect of adding vitamin D to
chemotherapy for the treatment of CRC. Although
Fig 4 Mean ± SD of tissue homogenate concentrations of (a) TGF-β1,
(b) HSP-90 and (c) COX-2 in the different study groups. (a = P < 0.05
compared with control group; b = P < 0.05 compared with AOM
group; c = P < 0.05 compared with 5-FU group and d = P < 0.05
compared with VitD group)
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fects of vitamin D3 and its analogues with 5-FU still
needs further investigations in clinical settings. Further-
more, the observed anti-cancer effects associated with
vitamin D could, to some extent, be a result of a positive
feedback mechanism on the production of VDR and/or
CaSR by colorectal mucosa.
Recently, it has been shown that enterocytes are
cable of synthesising active vitamin D independent
from the renal system since the colorectal mucosa
expresses VDR and vitamin D synthesising (CYP27B1)
and catabolising (CYP24A1) enzymes [47–51]. Coher-
ently, several in vivo and in vitro studies have also
shown that supplementation with vitamin D3 and
its analogues induced a significant increase in theexpression of VDR and CaSR by normal and cancer-
ous colorectal mucosa [22, 33–35, 52, 53]. However,
an increase in the expression of VDR and vitamin D
metabolising enzymes have also been documented in
early stages of differentiated CRC [51, 52, 54, 55]. Ac-
cordingly, further studies are still required to measure
the effect(s) of vitamin D3 ± 5-FU on the expression
of vitamin D metabolising enzymes, VDR and CaSR
in early and advanced CRC.
Vitamin D has been shown to regulate the signalling
mechanisms of several molecular pathways to prevent/
treat colon cancer. The development and progression of
colon cancer at the molecular level is complex and in-
volves disruption of several molecular pathways that
modulate cell growth, differentiation and angiogenesis.
Well documented pro-carcinogenic pathways include ab-
normal increase in the Wnt/β-catenin signals [9–11, 56],
HSP-90 [16–18], COX-2 and iNOS by colonic glandular
cells [12–15]. Moreover, inhibition of the TGF-β1 signals
in these cells through mutations in its type 2 receptor
and intracellular mediators is also associated with cancer
progression [6–8].
A variety of studies have shown that vitamin D pre-
vents cell proliferation and differentiation by inhibit-
ing the transcriptional activities of Wnt/β-catenin and
promoting the expression of TGF-β and its signalling
molecules through VDR [41, 57–59]. In this regard,
gene knockout of VDR in SW480-ADH cells in-
creased the transcriptional activities of β-catenin and
inhibited the suppressive effects of vitamin D on β-
catenin target genes [41]. More recently, vitamin D
has also been shown to inhibit the expression of
Wnt, β-catenin and their target genes in normal
colon cells in vitro and in vivo [60]. Vitamin D ana-
logues also inhibit the growth of xenograft models of
human colon cancer and this effect was achieved
through several mechanisms including increasing the
production of DKK-1, a pure inhibitor of Wnt/β-ca-
tenin signalling, expression in the xenografts [61, 62].
Similar effects have also been reported in chemically
induced model of colon cancer in rodents [63, 64].
Deregulation of the TGF-β1 signalling mechanism is
well documented in colon cancer and the cancer cells
develop resistance to the cytostatic effect of TGF-β1 by
mutations in the TGF-β type 2 receptor and deletion of
smad4 to allow cancer progression [6, 7, 65–68].
Although several studies have shown that vitamin D
modulates the expression of TGF-β1 and its related
molecules in a variety of tissues [69, 70], only a limited
number of reports in colon cancer are available. TGF-β
has been shown to promote the expression of VDR and
to regulate vitamin D signalling pathway through smad3
in vitro [71]. A later study has also demonstrated that
treatment with vitamin D up-regulated the expression of
Fig 5 Relative concentration of messenger RNA expression of (a) Wnt, (b) β-catenin, (c) DKK-1 and (d) COX-2. (a = P < 0.05 compared with control
group; b = P < 0.05 compared with AOM group; c = P < 0.05 compared with 5-FU group and d = P < 0.05 compared with VitD group)
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in human colonic epithelial CBS cells [72].
Our findings are in parallel with the previous studies
as they demonstrate that the observed reduction in the
numbers of colonic tumours was associated with a sig-
nificant decrease in the expression of β-catenin protein,
Wnt gene and significant increase in the DKK-1 mRNA,
TGF-β1, TGF-β type II receptor and smad4 proteins.
Furthermore, the most significant alteration in the ex-
pressions of the studied Wnt/β-catenin and TGF-β sig-
nalling molecules were detected in the ‘5-FU/D’ group.
Taken together, we suggest that the observed synergism
between both drugs on cancer cell growth and differenti-
ation could be mediated by several mechanisms includ-
ing inhibition of the Wnt canonical pathway and
promotion of the production of TGF-β signals. However,
future studies are required to measure the effects of
combining both drugs on the expression of the other
molecules involved in the regulation of Wnt canonical
(e.g. E-cadherin, TCF) and TGF-β (e.g. Smad2) pathways
in vitro and in vivo.
INOS and COX-2 play an important role, among other
molecules, in the promotion of colon cancer progressionthrough inducing angiogenesis and DNA damage [73–75].
Experimental studies have also reported that target inhib-
ition of these molecules is associated with less tumour
formation and/or regression of cancer [13, 76–78]. Add-
itionally, HSP-90 is essential for cancer progression and it
is overexpressed in several tumours including colon
cancer [17, 18]. The use of HSP90 inhibitors resulted in
the reduction of tumour invasiveness, tumour cell prolif-
eration, vascularisation and improvement in the efficacy
of chemotherapy [16].
Currently, the available data in the literature on the ef-
fects of vitamin D on the expression of iNOS, COX-2
and HSP-90 in colon cancer is limited. Hence, we hy-
pothesise that vitamin D could promote the efficacy of
5-FU and the regression of colon cancer by downregu-
lating the expression of iNOS, COX-2 and HSP-90 in
the colon mucosa to inhibit the processes of angio-
genesis and DNA damage. However, more studies are
needed to explore the role(s) of vitamin D and its recep-
tor in the regulation of these pathogenic molecules in
colon cancer to support our hypothesis.
In conclusion, our results suggest that vitamin D sup-
plementation promotes the efficacy of 5-FU during the
Refaat et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:71 Page 13 of 15treatment of colon cancer through synergistic interac-
tions that modulate cell growth, differentiation, apop-
tosis, angiogenesis and DNA damage by targeting several
pro- and anti-cancerous molecules. These molecular
pathways include Wnt/β-catenin pathway, TGF-β1 sig-
nals, iNOS, COX-2 and HSP-90. Further studies are
required to illustrate the clinical value of vitamin D
supplementation during the treatment of colon cancer
with 5-FU.
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